Eliem Therapeutics Net Income 2021-2024 | CLYM
Eliem Therapeutics net income from 2021 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Eliem Therapeutics Annual Net Income (Millions of US $) |
2023 |
$-35 |
2022 |
$-45 |
2021 |
$-52 |
2020 |
$-23 |
Eliem Therapeutics Quarterly Net Income (Millions of US $) |
2024-06-30 |
$-55 |
2024-03-31 |
$-2 |
2023-12-31 |
$-4 |
2023-09-30 |
$-4 |
2023-06-30 |
$-5 |
2023-03-31 |
$-22 |
2022-12-31 |
$-8 |
2022-09-30 |
$-10 |
2022-06-30 |
$-15 |
2022-03-31 |
$-13 |
2021-12-31 |
$-11 |
2021-09-30 |
$-11 |
2021-06-30 |
$-11 |
2021-03-31 |
$-20 |
2020-12-31 |
|
2020-09-30 |
$-3 |
2020-06-30 |
$-2 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-DRUGS |
$0.342B |
$0.000B |
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|